I A McNeish1, J A Ledermann2, L Webber2, L James2, S B Kaye3, M Hall4, G Hall5, A Clamp6, H Earl7, S Banerjee3, R Kristeleit8, F Raja2, A Feeney2, C Lawrence9, L Dawson-Athey9, M Persic10, I Khan2. 1. Institute of Cancer Sciences, University of Glasgow, Glasgow; Department of Medical Oncology, St Bartholomew's Hospital, London. Electronic address: iain.mcneish@glasgow.ac.uk. 2. CR UK and UCL Cancer Trials Centre, University College London, London. 3. Department of Medical Oncology, Royal Marsden Hospital, Sutton. 4. Division of Cancer Services, Mount Vernon Hospital, Northwood. 5. Leeds Cancer Centre, St James's University Hospital, Leeds. 6. Department of Medical Oncology, The Christie Hospital, Manchester. 7. Department of Oncology, Addenbrooke's Hospital, Cambridge. 8. Department of Medical Oncology, University College Hospital, London. 9. Department of Medical Oncology, St Bartholomew's Hospital, London. 10. Department of Oncology, Queen's Hospital, Burton upon Trent, UK.
Abstract
BACKGROUND: We investigated whether the Src inhibitor saracatinib (AZD0530) improved efficacy of weekly paclitaxel in platinum-resistant ovarian cancer. PATIENTS AND METHODS: Patients with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer were randomised 2 : 1 to receive 8-week cycles of weekly paclitaxel (wPxl; 80 mg/m(2)/week ×6 with 2-week break) plus saracatinib (S; 175 mg o.d.) or placebo (P) continuously, starting 1 week before wPxl, until disease progression. Patients were stratified by taxane-free interval (<6 versus ≥6 months/no prior taxane). The primary end point was progression-free survival (PFS) rate at 6 months. Secondary end points included overall survival (OS) and response rate (RR). RESULTS: A total of 107 patients, median age 63 years, were randomised. Forty-three (40%) had received >2 lines of prior chemotherapy. The 6-month PFS rate was 29% (wPxl + S) versus 34% (wPxl + P) (P = 0.582). Median PFS was 4.7 versus 5.3 months (hazard ratio 1.00, 95% confidence interval 0.65-1.54; P = 0.99). RR (complete + partial) was 29% (wPxl + S) versus 43% (wPxl + P), P value = 0.158. Grade 3/4 adverse events were 36% versus 31% (P = 0.624); the most frequent G3/4 toxicities were vomiting (5.8% saracatinib versus 8.6% placebo), abdominal pain (5.8% versus 0%) and diarrhoea (4.3% versus 5.7%). Febrile neutropenia was more common in the saracatinib arm (4.3%) than placebo (0%). Response, PFS and OS were all significantly (P < 0.05) better in patients with taxane interval ≥6 months/no prior taxane (n = 85) than those <6 months (n = 22), regardless of randomisation. CONCLUSIONS: Saracatinib does not improve activity of weekly paclitaxel in platinum-resistant ovarian cancer. Taxane-free interval of ≥6 months/no prior taxane was associated with better outcome in both groups. TRIALS REGISTRATION: Clinicaltrials.gov NCT01196741; ISRCTN 32163062.
BACKGROUND: We investigated whether the Src inhibitor saracatinib (AZD0530) improved efficacy of weekly paclitaxel in platinum-resistant ovarian cancer. PATIENTS AND METHODS: Patients with platinum-resistant ovarian, fallopian tube or primary peritoneal cancer were randomised 2 : 1 to receive 8-week cycles of weekly paclitaxel (wPxl; 80 mg/m(2)/week ×6 with 2-week break) plus saracatinib (S; 175 mg o.d.) or placebo (P) continuously, starting 1 week before wPxl, until disease progression. Patients were stratified by taxane-free interval (<6 versus ≥6 months/no prior taxane). The primary end point was progression-free survival (PFS) rate at 6 months. Secondary end points included overall survival (OS) and response rate (RR). RESULTS: A total of 107 patients, median age 63 years, were randomised. Forty-three (40%) had received >2 lines of prior chemotherapy. The 6-month PFS rate was 29% (wPxl + S) versus 34% (wPxl + P) (P = 0.582). Median PFS was 4.7 versus 5.3 months (hazard ratio 1.00, 95% confidence interval 0.65-1.54; P = 0.99). RR (complete + partial) was 29% (wPxl + S) versus 43% (wPxl + P), P value = 0.158. Grade 3/4 adverse events were 36% versus 31% (P = 0.624); the most frequent G3/4 toxicities were vomiting (5.8% saracatinib versus 8.6% placebo), abdominal pain (5.8% versus 0%) and diarrhoea (4.3% versus 5.7%). Febrile neutropenia was more common in the saracatinib arm (4.3%) than placebo (0%). Response, PFS and OS were all significantly (P < 0.05) better in patients with taxane interval ≥6 months/no prior taxane (n = 85) than those <6 months (n = 22), regardless of randomisation. CONCLUSIONS: Saracatinib does not improve activity of weekly paclitaxel in platinum-resistant ovarian cancer. Taxane-free interval of ≥6 months/no prior taxane was associated with better outcome in both groups. TRIALS REGISTRATION: Clinicaltrials.gov NCT01196741; ISRCTN 32163062.
Authors: Angeles Alvarez Secord; Deanna Teoh; Jingquan Jia; Andrew B Nixon; Lisa Grace; David J Adams; Susan K Murphy Journal: Int J Gynecol Cancer Date: 2014-02 Impact factor: 3.437
Authors: Carin K Ingemarsdotter; Laura A Tookman; Ashley Browne; Katrina Pirlo; Rosalind Cutts; Claude Chelela; Karisma F Khurrum; Elaine Y L Leung; Suzanne Dowson; Lee Webber; Iftekhar Khan; Darren Ennis; Nelofer Syed; Tim R Crook; James D Brenton; Michelle Lockley; Iain A McNeish Journal: Mol Oncol Date: 2014-12-29 Impact factor: 6.603
Authors: Marwa Asem; Allison M Young; Carlysa Oyama; Alejandro Claure De La Zerda; Yueying Liu; Jing Yang; Tyvette S Hilliard; Jeffery Johnson; Elizabeth I Harper; Ian Guldner; Siyuan Zhang; Toni Page-Mayberry; William J Kaliney; M Sharon Stack Journal: Cancer Res Date: 2020-01-13 Impact factor: 12.701
Authors: S M Reddy; S Kopetz; J Morris; N Parikh; W Qiao; M J Overman; D Fogelman; I Shureiqi; C Jacobs; Z Malik; C A Jimenez; R A Wolff; J L Abbruzzese; G Gallick; C Eng Journal: Invest New Drugs Date: 2015-06-12 Impact factor: 3.850
Authors: Hyun-Jin Choi; Guillermo N Armaiz Pena; Sunila Pradeep; Min Soon Cho; Robert L Coleman; Anil K Sood Journal: Cancer Metastasis Rev Date: 2015-03 Impact factor: 9.264
Authors: Cassie J Clarke; Tracy J Berg; Joanna Birch; Darren Ennis; Louise Mitchell; Catherine Cloix; Andrew Campbell; David Sumpton; Colin Nixon; Kirsteen Campbell; Victoria L Bridgeman; Peter B Vermeulen; Shane Foo; Eleftherios Kostaras; J Louise Jones; Linda Haywood; Ellie Pulleine; Huabing Yin; Douglas Strathdee; Owen Sansom; Karen Blyth; Iain McNeish; Sara Zanivan; Andrew R Reynolds; Jim C Norman Journal: Curr Biol Date: 2016-03-03 Impact factor: 10.834